A Dual‐Key Gated Nuclear‐DNA‐Targeted Photogenerator for Amplified Photodynamic Immunotherapy of Breast Cancer

utilized photogenerated highly toxic hydroxyl radical (·OH) in situ to damage the nucleus even under hypoxia, causing the up-regulated expression of related genes (DDI2, KDM4D, RGCC). Concomitantly, damage-associated high-mobility group box 1 (HMGB1) and calreticulin (CRT) were released, triggering a systemic immune response to further suppress distant tumors, realizing efficient PDIT for breast cancer. This study provides new insight into designing nuclear-DNA-targeted phototherapeutic agents for complete ablation of metastatic tumors.